Elevation of a tumor associated antigen CA 19-9 levels in patients with rheumatic diseases.
1989; National Institutes of Health; Volume: 16; Issue: 11 Linguagem: Inglês
Autores
C Shimomura, Katsumi Eguchi, Ayako Kawakami, Kiyoshi Migita, Haruhisa Nakao, Takehito Otsubo, Yukitaka Ueki, Hiroshi Tezuka, Shunichi Yamashita, Mayumi Matsunaga,
Tópico(s)Lymphoma Diagnosis and Treatment
ResumoWe investigated the incidence and characteristics of an elevated tumor associated antigen CA 19-9 in patients with rheumatic diseases. Serum concentration of CA 19-9 was increased in 13 of 39 patients (33.3%) with definite or classical rheumatoid arthritis (RA), in 6 of 19 patients (31.6%) with systemic lupus erythematosus (SLE), in 3 of 9 patients (33.3%) with progressive systemic sclerosis (PSS) and in 9 of the other 35 patients (25.7%). Malignant neoplasm was not detected in any of the patients with rheumatic diseases. Pretreatment of mouse serum with patients' sera did not reduce the measured CA 19-9 values obtained by the conventional assay. The CA 19-9 antigen found in sera from patients with RA was present in a non-IgG fraction, and had the same molecular weight as that in one patient with pancreatic cancer, as determined by gel filtration. These results demonstrated that serum CA 19-9 levels were increased in some patients with rheumatic diseases.
Referência(s)